ProCE Banner Activity

ECHO-202/KEYNOTE-037: Phase I/II Study of Epacadostat + Pembrolizumab in Pts With Advanced RCC

Slideset Download
Conference Coverage
Epacadostat plus pembrolizumab safe, active in patients with advanced RCC with 47% ORR in patients who received ≤ 1 previous line of therapy.

Released: June 08, 2017

Expiration: June 07, 2018

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants by

AbbVie

Amgen, Inc.

AstraZeneca

Celgene

Genentech Roche Virology

Halozyme

Incyte

Merck Oncology